105 related articles for article (PubMed ID: 38874196)
1. MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.
Karin M; Kim JY
Mol Oncol; 2024 Jun; ():. PubMed ID: 38874196
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study.
Yang DL; Liu SP; Wang HL; Li JR; Su JY; Li MJ; Teng YX; Deng ZJ; Li ZH; Huang JL; Guo PP; Ma L; Li ZZ; Zhong JH
Infect Agent Cancer; 2024 May; 19(1):21. PubMed ID: 38693556
[TBL] [Abstract][Full Text] [Related]
3. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma.
Chen VL; Yeh ML; Yang JD; Leong J; Huang DQ; Toyoda H; Chen YL; Guy J; Maeda M; Tsai PC; Huang CF; Yasuda S; Le AK; Dang H; Giama NH; Ali HA; Zhang N; Wang X; Jun DW; Tseng CH; Hsu YC; Huang JF; Dai CY; Chuang WL; Zhu Q; Dan YY; Schwartz M; Roberts LR; Yu ML; Nguyen MH
Hepatol Commun; 2021 Jan; 5(1):122-132. PubMed ID: 33437906
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review.
Ghazanfar H; Javed N; Qasim A; Zacharia GS; Ghazanfar A; Jyala A; Shehi E; Patel H
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539547
[TBL] [Abstract][Full Text] [Related]
5. Insight into the regulatory mechanism of m
Zha X; Gao Z; Li M; Xia X; Mao Z; Wang S
Biomed Pharmacother; 2024 Jun; 177():116966. PubMed ID: 38906018
[TBL] [Abstract][Full Text] [Related]
6. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.
Huang SC; Su TH; Tseng TC; Chen CL; Hsu SJ; Liao SH; Hong CM; Liu CH; Lan TY; Yang HC; Liu CJ; Chen PJ; Kao JH
Hepatol Int; 2023 Oct; 17(5):1139-1149. PubMed ID: 37247045
[TBL] [Abstract][Full Text] [Related]
7. NAFLD and MAFLD as emerging causes of HCC: A populational study.
Myers S; Neyroud-Caspar I; Spahr L; Gkouvatsos K; Fournier E; Giostra E; Magini G; Frossard JL; Bascaron ME; Vernaz N; Zampaglione L; Negro F; Goossens N
JHEP Rep; 2021 Apr; 3(2):100231. PubMed ID: 33748726
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.
Xiong KG; Ke KY; Kong JF; Lin TS; Lin QB; Lin S; Zhu YY
World J Surg Oncol; 2024 May; 22(1):117. PubMed ID: 38698475
[TBL] [Abstract][Full Text] [Related]
9. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy.
Guo F; Estévez-Vázquez O; Benedé-Ubieto R; Maya-Miles D; Zheng K; Gallego-Durán R; Rojas Á; Ampuero J; Romero-Gómez M; Philip K; Egbuniwe IU; Chen C; Simon J; Delgado TC; Martínez-Chantar ML; Sun J; Reissing J; Bruns T; Lamas-Paz A; Moral MGD; Woitok MM; Vaquero J; Regueiro JR; Liedtke C; Trautwein C; Bañares R; Cubero FJ; Nevzorova YA
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008356
[TBL] [Abstract][Full Text] [Related]
10. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Casalino A; Bocca C; Novo E; Protopapa F; Ramavath NN; Provera A; Gambella A; Bugianesi E; Tacke F; Albano E; Parola M
Front Immunol; 2024; 15():1342404. PubMed ID: 38469298
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
12. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
[TBL] [Abstract][Full Text] [Related]
13. Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.
Xue J; Wang QX; Xiao HM; Shi MJ; Xie YB; Li S; Lin M; Chi XL
Cancer Manag Res; 2022; 14():2193-2202. PubMed ID: 35859711
[TBL] [Abstract][Full Text] [Related]
14. Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems.
Córdova-Gallardo J; Keaveny AP; Qi X; Méndez-Sánchez N
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e84-e93. PubMed ID: 34985050
[TBL] [Abstract][Full Text] [Related]
15. Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma.
Xie X; Zheng M; Guo W; Zhou Y; Xiang Z; Li Y; Yang J
Sci Rep; 2022 Aug; 12(1):13969. PubMed ID: 35978032
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis antagonizing transcription factor-mediated liver damage and inflammation to cancer: Therapeutic intervention by curcumin in experimental metabolic dysfunction associated steatohepatitis-hepatocellular carcinoma.
Srinivas AN; Suresh D; Chidambaram SB; Santhekadur PK; Kumar DP
J Cell Physiol; 2024 Jan; 239(1):135-151. PubMed ID: 37942831
[TBL] [Abstract][Full Text] [Related]
17. Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma.
Song BG; Choi SC; Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW
JHEP Rep; 2023 Sep; 5(9):100810. PubMed ID: 37538246
[TBL] [Abstract][Full Text] [Related]
18. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease.
Gish R; Fan JG; Dossaji Z; Fichez J; Laeeq T; Chun M; Boursier J
Hepatol Int; 2024 Jun; ():. PubMed ID: 38850496
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
Fassio E; Barreyro FJ; Pérez MS; Dávila D; Landeira G; Gualano G; Ruffillo G
World J Hepatol; 2022 Feb; 14(2):354-371. PubMed ID: 35317172
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]